SCHEMBL5493098

SCHEMBL5493098

COC(=O)/C(O)=C\C(=O)c1ccncc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.46
MAPT P10636 4/20 0.46
HPGD P15428 4/20 0.46
LMNA P02545 4/20 0.46
GAA P10253 3/20 0.46
TSHR P16473 1/20 0.46
NFKB1 P19838 1/20 0.46
MAPK1 P28482 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
CYP1A2 P05177 9/20 0.45
CYP2D6 P10635 8/20 0.45
CYP1A1 P04798 7/20 0.45
CYP1B1 Q16678 7/20 0.45
HTT P42858 2/20 0.45
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44
NAPRT Q6XQN6 1/20 0.44
ALDH1A1 P00352 3/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2239090 1.00 POLB (0.46) POLBMAPTHPGDLMNAGAA
SCHEMBL2239088 1.00 POLB (0.46) POLBMAPTHPGDLMNAGAA
SCHEMBL2232374 0.84 NFE2L2 (0.53) POLBMAPTLMNAGAATSHR
SCHEMBL3310563 0.84 NFE2L2 (0.53) POLBMAPTLMNAGAATSHR
SCHEMBL2232370 0.84 NFE2L2 (0.53) POLBMAPTLMNAGAATSHR
SCHEMBL933237 0.82 MAPT (0.45) MAPTHPGDLMNAGAATSHR
SCHEMBL933235 0.82 MAPT (0.45) MAPTHPGDLMNAGAATSHR
SCHEMBL629545 0.81 ALDH1A1 (0.57) MAPTHPGDLMNAGAACYP1A2
SCHEMBL629546 0.81 ALDH1A1 (0.57) MAPTHPGDLMNAGAACYP1A2
SCHEMBL2231488 0.81 ALDH1A1 (0.60) MAPTHPGDLMNAGAACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1799206-A2 PYRAZOLE DERIVATIVES FOR TREATING CONDITIONS MEDIATED BY ACTIVATION OF THE ADENOSINE A2B OR A3 RECEPTOR Novartis AG (CH) 2007-06-27 EP disclosed
WO-2006015860-A2 PYRAZOLE DERIVATIVES FOR TREATING CONDITIONS MEDIATED BY ACTIVATION OF THE ADENOSINE A2B OR A3 RECEPTOR NOVARTIS AG (CH) 2006-02-16 WO disclosed